GE Healthcare is going beyond just selling diagnostic imaging products in India to get involved, in part, in the distribution of care. The company will team up with a U.S. cancer healthcare operator to open cancer clinics that will rely on some of its key technology.
Intuitive Surgical is facing legal pushback from shareholders who claim that the company underreported adverse events and concealed recalls from the FDA related to its robotic surgical device, MassDevice reported.
Chembio announced Tuesday it has received approval to begin marketing its rapid point-of-care HIV test, the HIV 1/2 Stat-Pak Assay, in Europe.
Ariosa Diagnostics filed plans for an IPO worth as much as $69 million that it will use to heighten commercialization efforts for its Harmony prenatal genetic test.
LabCorp is bringing on a new chief financial officer, a key position for the diagnostics and genomic testing outfit as it seeks to recharge sales, emerge from a restructuring and combat ongoing insurance reimbursement challenges.
GE Healthcare has developed a discount molecular imaging system for cancer detection, intended for physicians practicing personalized medicine in emerging markets--especially India, where the devicemaker got help designing the system.
DexCom, a maker of continuous glucose monitoring systems, got slapped with an FDA warning letter for falling short in its medical device reporting procedures.
As interest in NeuroPace's new RNS neuromodulation antiepilepsy implant ramps up, The New York Times tracked down some of the patients who use the device and have experienced major improvements in their quality of life.
Hot on the trail of new M&A deals, Stryker finalized its acquisition of Patient Safety Technologies. The Kalamazoo, MI-based company paid $120 million for the medical device outfit, gaining access to Patient Safety's line of trackable surgical tools.
Axonics Modulation Technologies got itself a $32.6 million Series A funding round that will help advance its implantable neuromodulation technology into human clinical studies to treat a variety of conditions.
Sequenom said it has settled a long-standing lawsuit filed by its ex-CFO alleging defamation in connection with an R&D scandal.
Quest Diagnostics has gained expedited U.S. clearance for a new rapid test designed to help diagnose encephalitis.
St. Jude Medical is confronting a flat pacemaker market and continued fallout from faulty defibrillator leads with a rollout of new products in both spaces. The hope: Next-generation improvements will spur new market interest and greater revenue.
Oncology biotech Tesaro will use a cancer test developed by Myriad Genetics to look for tumor types that may respond to PARP inhibitors like niraparib, a Phase III candidate in ovarian cancer and breast cancer, in-licensed from Merck in 2012.
GE Healthcare completed its acquisition of three Thermo Fisher Scientific units. The $1.1 billion deal gives GE access to Thermo Fisher's profitable cell culture, gene modulation and magnetic bead businesses, helping the company expand its presence in protein analysis and medical diagnostics.
In 2013, a number of outside forces hammered the med tech industry. While things could have been better, most of the top 10 companies in the sector still enjoyed moderate year-over-year revenue gains.
Business Korea reported that the government has a goal for its med tech industry to export more than $12.5 billion worth of goods, hire 130,000 people and have a 3.8% global market share by 2020.
St Jude Medical got hammered with a new lawsuit from a Pennsylvania man who claims the company's now-recalled Riata cardiac defibrillator leads injured him. The latest Riata legal fight underscores the reality that fallout from the product's problems won't be going away any time soon.
Navidea Biopharmaceuticals met with European regulators who hold the key to approving its Lymphoseek injectable diagnostic imaging agent, and the company said it has met the benchmarks it needs to gain market authorization.
Not long after digesting its $450 million buyout of BioFire Diagnostics, bioMérieux seems to be on the hunt for another acquisition. Reuters reported recently that the French company is eyeing Siemens' microbiology unit.